- Home
- TECH vs HALO Comparison
TECH vs HALO Comparison
Compare TECH & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TECH
- HALO
- Stock Information
- Founded
- TECH 1976
- HALO 1998
- Country
- TECH United States
- HALO United States
- Employees
- TECH N/A
- HALO N/A
- Industry
- TECH Biotechnology: Biological Products (No Diagnostic Substances)
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TECH Health Care
- HALO Health Care
- Exchange
- TECH Nasdaq
- HALO Nasdaq
- Market Cap
- TECH 8.9B
- HALO 7.6B
- IPO Year
- TECH 1989
- HALO N/A
- Fundamental
- Price
- TECH $64.75
- HALO $73.13
- Analyst Decision
- TECH Strong Buy
- HALO Buy
- Analyst Count
- TECH 14
- HALO 12
- Target Price
- TECH $71.23
- HALO $73.33
- AVG Volume (30 Days)
- TECH 2.1M
- HALO 2.7M
- Earning Date
- TECH 11-05-2025
- HALO 11-03-2025
- Dividend Yield
- TECH 0.50%
- HALO N/A
- EPS Growth
- TECH N/A
- HALO 56.68
- EPS
- TECH 0.49
- HALO 4.74
- Revenue
- TECH $1,216,732,000.00
- HALO $1,242,852,000.00
- Revenue This Year
- TECH $3.64
- HALO $32.47
- Revenue Next Year
- TECH $7.59
- HALO $24.31
- P/E Ratio
- TECH $132.78
- HALO $15.34
- Revenue Growth
- TECH 3.85
- HALO 31.19
- 52 Week Low
- TECH $46.01
- HALO $46.26
- 52 Week High
- TECH $79.28
- HALO $79.50
- Technical
- Relative Strength Index (RSI)
- TECH 62.28
- HALO 63.53
- Support Level
- TECH $57.02
- HALO $68.09
- Resistance Level
- TECH $66.06
- HALO $70.81
- Average True Range (ATR)
- TECH 2.06
- HALO 2.26
- MACD
- TECH 0.56
- HALO 0.46
- Stochastic Oscillator
- TECH 86.04
- HALO 80.82
About TECH Bio-Techne Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.